KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Retained Earnings (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Retained Earnings for 15 consecutive years, with -$1.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 99.92% year-over-year to -$1.2 million, compared with a TTM value of -$1.2 million through Dec 2025, up 99.92%, and an annual FY2025 reading of -$1.2 million, up 99.92% over the prior year.
  • Retained Earnings was -$1.2 million for Q4 2025 at Travere Therapeutics, up from -$1.5 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$262000.0 in Q1 2021 and bottomed at -$1.5 billion in Q1 2025.
  • Average Retained Earnings over 5 years is -$606.6 million, with a median of -$740.2 million recorded in 2021.
  • The sharpest move saw Retained Earnings plummeted 309713.74% in 2022, then soared 99.92% in 2025.
  • Year by year, Retained Earnings stood at -$766.0 million in 2021, then tumbled by 32.41% to -$1.0 billion in 2022, then skyrocketed by 99.86% to -$1.5 million in 2023, then tumbled by 99293.34% to -$1.4 billion in 2024, then skyrocketed by 99.92% to -$1.2 million in 2025.
  • Business Quant data shows Retained Earnings for TVTX at -$1.2 million in Q4 2025, -$1.5 billion in Q3 2025, and -$812000.0 in Q2 2025.